MedTrace Logo

A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers

NCT05366634 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-05-08

No results posted yet for this study

Summary

MDK-703-101 is a single ascending dose study, to determine the safety, tolerability, and PK/PD of MDK-703 in healthy adult subjects.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

MDK-703 or Placebo

Injection

Sponsors & Collaborators

  • Medikine Australia Pty Ltd.

    collaborator UNKNOWN

  • Medikine, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2022-12-28
Completion
2022-12-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366634 on ClinicalTrials.gov